INCY News and Press, Incyte Corporation From 01/23/24

Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2023 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 13, 2024. The schedule for the press release and conference call/webcast is as follows: Q4 & YE 2023 Pr...

2024-01-11 07:53:52 ET More on Aclaris Therapeutics Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report Aclaris downgraded at Jefferies despite mid-stage win for eczema therapy Aclaris posts topline data from mid-stage trial for eczema therapy ...

Presentation underscores potential of several high-impact launches across Oncology and Inflammation & Autoimmunity to drive sustainable long-term growth Company announces new positive topline results from Phase 2 trial evaluating ruxolitinib cream (Opzelura ® ) in adults with...

2024-01-05 14:30:17 ET More on the markets SPY And QQQ: Fundamentals Remain Strong, Buying The Dip Verily Volatility: SPY Puts Are Cheap And The Market Is Selling Off The Market Looks Poised To Make New Highs In 2024 ETFs attract $597B in 2023 marking the fou...

2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...

2023-12-26 11:15:43 ET Summary Syndax Pharmaceuticals, Inc. has experienced a roller coaster ride in the stock market, but is currently up 80% from its lows in October. The company has two candidates in development that are poised to garner FDA approval in 2024 and also just fille...

2023-12-21 13:05:16 ET Summary Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions. ...

2023-12-18 09:00:00 ET Summary Incyte stock has experienced significant volatility and decline throughout the year. INCY is focused on updating its revenue base but lacks any strong near term catalysts. Incyte has a pending LOE issue. This is my second Incyte (INCY) ...

2023-12-15 14:30:49 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips As technology advances in our era, biotechnology is not far behind. Modern day medical advancements are impressive, and the company’s making these strides have incredible results to show...

2023-12-14 14:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...